Skip to content

Study · Observational study · n = 651 · 2025

5 results

Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.

Rudofsky G, Menzen M, Potier L, Catarig AM, Clark A, Priyadarshini P, Abreu C

Advances in therapy5 Dec 2024Cited by 4 (Europe PMC)

PMID39636564 (opens in a new tab)PMCIDPMC11787244 (opens in a new tab)DOI10.1007/s12325-024-03000-x (opens in a new tab)PepBankPUB-39636564
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who switched from another GLP-1 receptor agonist to once-weekly semaglutide, HbA1c fell by 0.67 percentage points over 30 weeks.

    In plain wordsIn adults with type 2 diabetes who switched to once-weekly semaglutide from another GLP-1 drug, HbA1c fell over 30 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change after switching to once-weekly semaglutide
    Study

    n = 651

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.67 %-point
    switchers

    Source sentences

    Summary
    GLP-1RA-experienced patients who switched to OW semaglutide demonstrated a 0.67%-point [95% confidence interval (CI) - 0.74; - 0.60, p 1c
    2 context sentences
    Summary · context
    This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice.
    Summary · context
    Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA1c), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA1c value within the 12 weeks before switching to OW semaglutide.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who switched from another GLP-1 receptor agonist to once-weekly semaglutide, body weight fell by 3.69 kg over 30 weeks.

    In plain wordsIn adults with type 2 diabetes who switched to once-weekly semaglutide from another GLP-1 drug, body weight fell over 30 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change after switching to once-weekly semaglutide
    Study

    n = 651

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    Body weight change
    −3.69 kg
    switchers

    Source sentences

    Summary
    a 3.69-kg [95% CI - 3.98; - 3.41, p < 0.0001] reduction in body weight over 30 weeks.
    2 context sentences
    Summary · context
    This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice.
    Summary · context
    Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA1c), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA1c value within the 12 weeks before switching to OW semaglutide.
  3. 03HumanObservational studySafety outcome

    In adults with type 2 diabetes who switched to once-weekly semaglutide, no new safety concerns were identified.

    In plain wordsIn adults with type 2 diabetes who switched to once-weekly semaglutide, no new safety concerns were found.

    Peptide
    Semaglutide
    Outcome
    No significant changeSafety after switching to once-weekly semaglutide
    Study

    n = 651

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    No new safety concerns were identified.
    2 context sentences
    Summary · context
    This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice.
    Summary · context
    Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA1c), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA1c value within the 12 weeks before switching to OW semaglutide.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who switched to once-weekly semaglutide, 27.6% achieved a body weight reduction of 5% or more.

    In plain wordsIn adults with type 2 diabetes who switched to once-weekly semaglutide, 27.6% lost at least 5% of body weight.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion with body weight reduction of 5% or more
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    Proportion with weight loss >=5%
    27.6%
    switchers

    Source sentences

    Summary
    A body weight reduction of ≥ 5% was achieved by 27.6% of patients, and 33.3% of patients with baseline HbA1c ≥ 7% achieved HbA1c < 7% at end of study.
    2 context sentences
    Summary · context
    This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice.
    Summary · context
    Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA1c), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA1c value within the 12 weeks before switching to OW semaglutide.
  5. 05HumanObservational studyEfficacy outcome

    Among adults with type 2 diabetes and baseline HbA1c of 7% or more who switched to once-weekly semaglutide, 33.3% reached HbA1c below 7% at end of study.

    In plain wordsAmong adults with type 2 diabetes and HbA1c of 7% or more who switched to once-weekly semaglutide, 33.3% reached HbA1c below 7%.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion with HbA1c below 7% at end of study
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    Proportion with HbA1c <7%
    33.3%
    baseline HbA1c >=7%

    Source sentences

    Summary
    33.3% of patients with baseline HbA1c ≥ 7% achieved HbA1c < 7% at end of study.
    2 context sentences
    Summary · context
    This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice.
    Summary · context
    Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA1c), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA1c value within the 12 weeks before switching to OW semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.